Author

Samanta Gutierrez

Institution: Vaxart (United States)

Observed institution: Vaxart (United States)

ORCID: 0009-0005-3252-8867

Observed ORCID: 0009-0005-3252-8867

OpenAlex ID: A5028832578

An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial

2025 · Becca A. Flitter, Susan N. Greco, et al. · Science Translational Medicine · 20

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial

2022 · Susan Johnson, Clarissa I Martinez, et al. · medRxiv · 17

A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates

2024 · Sarah N. Tedjakusuma, Colin A. Lester, et al. · Vaccines · 2

Oral tablet vaccination against SARS-CoV-2 spike boosts cross-reactive serum and mucosal neutralizing antibodies following mRNA vaccination: a phase 2 clinical trial

2023 · Susan Johnson, Clara B Jegede, et al. · The Journal of Immunology

Works count: 4

Citation count: 39

H-index: 2

I10-index: 2